glp-1 gip 2ra Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes Dual GLP-1/GIP receptor agonists mechanism

Since responses to treatment differ from person to person, personalized care is essential

Once-daily oral semaglutide (Rybelsus) achieves an HbA 1c reduction of around 1115 mmol/mol in people with type 2 diabetes less than injectable semaglutide but comparable to other long-acting injectable GLP-1 RAs

The multiple-dose regimen, given for up to 4 weeks, led to a dose-dependent weight loss between 2.87 and 5.46 kg, compared to 2.37 kg for placebo

The way through is to assign each measure an explicit job before the trial starts rather than after the results arrive

Quan H, Sundararajan V, Halfon P, et al

Press release May 11 2020